US EditionAcousia Therapeutics Reaches 50% Enrollment in Phase 2 PROHEAR Study Evaluating Hearing Loss Prevention in Cancer Patients | Hearing Health & Technology Matters
Summary by hearinghealthmatters.org
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Acousia Therapeutics Reaches 50% Enrollment in Phase 2 PROHEAR Study Evaluating Hearing Loss Prevention in Cancer Patients | Hearing Health & Technology Matters
Tübingen, Germany – Acousia Therapeutics GmbH announced it has reached the 50% enrollment milestone in its ongoing Phase 2 clinical trial, known as the PROHEAR Study. The trial is evaluating ACOU085 (INN: bimokalner), a Kv7.4 channel activator, for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is widely used in modern oncology, with more than 500,000 patients treated annual…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
